BR112022006085A2 - Composições que potencializam preferencialmente subtipos de receptores de gabaa e métodos de uso das mesmas - Google Patents
Composições que potencializam preferencialmente subtipos de receptores de gabaa e métodos de uso das mesmasInfo
- Publication number
- BR112022006085A2 BR112022006085A2 BR112022006085A BR112022006085A BR112022006085A2 BR 112022006085 A2 BR112022006085 A2 BR 112022006085A2 BR 112022006085 A BR112022006085 A BR 112022006085A BR 112022006085 A BR112022006085 A BR 112022006085A BR 112022006085 A2 BR112022006085 A2 BR 112022006085A2
- Authority
- BR
- Brazil
- Prior art keywords
- compositions
- methods
- gabaa
- receptor subtypes
- gabaa receptor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962907763P | 2019-09-30 | 2019-09-30 | |
PCT/US2020/052167 WO2021067089A1 (en) | 2019-09-30 | 2020-09-23 | Compositions that preferentially potentiate subtypes of gabaa receptors and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022006085A2 true BR112022006085A2 (pt) | 2023-03-14 |
Family
ID=75338529
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022006085A BR112022006085A2 (pt) | 2019-09-30 | 2020-09-23 | Composições que potencializam preferencialmente subtipos de receptores de gabaa e métodos de uso das mesmas |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP4135710A4 (zh) |
JP (1) | JP2022552788A (zh) |
KR (1) | KR20220103707A (zh) |
CN (1) | CN115087450A (zh) |
BR (1) | BR112022006085A2 (zh) |
CA (1) | CA3159087A1 (zh) |
IL (1) | IL291835A (zh) |
MX (1) | MX2022003823A (zh) |
WO (1) | WO2021067089A1 (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4161530A4 (en) * | 2020-06-08 | 2024-06-26 | Eliem Therapeutics (UK) Ltd | METHODS FOR TREATING FEMALE HEALTH CONDITIONS RELATED TO SEX HORMONES |
WO2024020953A1 (zh) * | 2022-07-28 | 2024-02-01 | 湖南科益新生物医药有限公司 | 治疗中枢神经系统疾病的甾体化合物及其制备方法、用途和药物组合物 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5939545A (en) * | 1994-02-14 | 1999-08-17 | Cocensys, Inc. | Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series |
PT3498725T (pt) * | 2013-04-17 | 2021-09-09 | Sage Therapeutics Inc | Esteroides c21-n-pirazolilo 19-nor c3,3-dissubstituídos para uso em terapia |
WO2016061527A1 (en) * | 2014-10-16 | 2016-04-21 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
CN109890392A (zh) * | 2016-10-14 | 2019-06-14 | 马瑞纳斯制药公司 | 施用神经类固醇以实现脑电图(eeg)爆发抑制的方法 |
WO2020210116A1 (en) * | 2019-04-08 | 2020-10-15 | Athenen Therapeutics, Inc. | Steroids with altered pharmacokinetic properties and methods of use thereof |
-
2020
- 2020-09-23 JP JP2022519997A patent/JP2022552788A/ja active Pending
- 2020-09-23 MX MX2022003823A patent/MX2022003823A/es unknown
- 2020-09-23 CN CN202080082811.4A patent/CN115087450A/zh active Pending
- 2020-09-23 KR KR1020227014562A patent/KR20220103707A/ko active Search and Examination
- 2020-09-23 BR BR112022006085A patent/BR112022006085A2/pt unknown
- 2020-09-23 WO PCT/US2020/052167 patent/WO2021067089A1/en unknown
- 2020-09-23 EP EP20872608.3A patent/EP4135710A4/en active Pending
- 2020-09-23 IL IL291835A patent/IL291835A/en unknown
- 2020-09-23 CA CA3159087A patent/CA3159087A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3159087A1 (en) | 2021-04-08 |
EP4135710A4 (en) | 2023-12-06 |
IL291835A (en) | 2022-06-01 |
EP4135710A1 (en) | 2023-02-22 |
WO2021067089A1 (en) | 2021-04-08 |
CN115087450A (zh) | 2022-09-20 |
JP2022552788A (ja) | 2022-12-20 |
KR20220103707A (ko) | 2022-07-22 |
MX2022003823A (es) | 2022-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2022001271A1 (es) | Agonista del receptor glp-1 y uso de este | |
CO2022002759A2 (es) | Antagonistas de hpk1 y sus usos | |
CO2021007068A2 (es) | Degradadores de irak y usos de los mismos | |
CL2021003190A1 (es) | Inhibidores de tead y usos de los mismos | |
CL2018001845A1 (es) | Moduladores de la 5'-nucleotidasa, ecto y su uso | |
CO2021001893A2 (es) | Anticuerpos anti-gdf15, composiciones y métodos de uso | |
DOP2022000182A (es) | Conjugados de anticuerpo y fármaco anti-egfr | |
DOP2017000298A (es) | Reguladores de nrf2 | |
ECSP22055515A (es) | Compuestos y métodos para la degradación dirigida del receptor de andrógenos | |
CO2022008406A2 (es) | Degradadores de irak y usos de los mismos | |
GT201600233A (es) | Compuestos y composiciones como agonistas del receptor tipo toll 7 | |
UY37274A (es) | Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos | |
CO2021013339A2 (es) | Degradadores de stat y usos de los mismos | |
BR112022006085A2 (pt) | Composições que potencializam preferencialmente subtipos de receptores de gabaa e métodos de uso das mesmas | |
UY37589A (es) | COMPUESTOS MODULADORES DEL RECEPTOR DE HIDROCARBUROS ARÍLICOS (AhR) | |
UY37590A (es) | COMPUESTOS MODULADORES DEL RECEPTOR DE HIDROCARBUROS ARÍLICOS (AhR) | |
CL2018002810A1 (es) | Anticuerpos anti-factor bb del complemento y usos de estos referencia cruzada. | |
CO2020015747A2 (es) | Analogos de rapamicina y usos de los mismos | |
CL2021002357A1 (es) | Compuestos piperidinil bicíclicos fusionados y relacionados como modulares del receptor c5a | |
DK3721227T3 (da) | Olfaktorisk receptor involveret i opfattelsen af moskusduftstof og anvendelsen deraf | |
ECSP21088669A (es) | Anticuerpos de receptor de péptido natriurético 1 y métodos de uso | |
DOP2018000238A (es) | Inhibidores del potenciador del homólogo zeste 2 | |
CL2019001991A1 (es) | Moduladores del receptor de estrógeno. | |
CL2021001027A1 (es) | Inhibidores selectivos de rgmc y el uso de los mismos | |
CO7240378A2 (es) | Indolcarbonitrilos como moduladores selectivos de los receptores de andrógeno |